A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience

Abstract

Context Nilotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML).

Aims We aim to evaluate the responses and safety of upfront Nilotinib therapy in Indian CML patients.

Setting and Design We retrospectively reviewed the medical records of CML patients who received Nilotinib as an upfront treatment at our center between January 1, 2011 and October 15, 2019.The follow-up was taken till March 31, 2020.

Results Forty One patients (n = 36 chronic phase and five accelerated-phase CML) received frontline Nilotinib. Median age was 39 years (21–63) with male-to-female ratio of 1.1: 1. At 3 months, 96.9% patients achieved BCR-ABL of ≤10% at international scale. By the end of 12 months, 71.5% patients achieved major molecular response (BCR-ABL ≤0.1%) and 91.4% patients achieved complete cytogenetic response assessed by BCR-ABL polymerase chain reaction of ≤1%. Common toxicities observed were weight gain, thrombocytopenia, corrected QT prolongation, and elevated serum amylase in 14 (34.1%), 7(17.07%), 4(9.7%), and 4(9.7%) patients, respectively. Overall, five patients had loss of response with further progression and death in three patients. At a median of 43.7 months, 38 patients survived with estimated 3 year event-free survival and overall survival of 65 ± 9 and 93 ± 5%.

Conclusion This study showed remarkable good response with upfront Nilotinib in Indian patients with CML.

Keywords

Upfront Nilotinib - Early molecular response - Major molecular response - Chronic myeloid leukemia - Toxicity

Publikationsverlauf

Artikel online veröffentlicht:
24. November 2021

• References

• 1 Bansal S. Is imatinib still the best choice as first-line oral TKI. South Asian J Cancer 2014; 3 (01) 83-86
• 2 Larson RA, Hochhaus A, Hughes TP. et al Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26 (10) 2197-2203
• 3 Jayakar V. Using 2(nd) generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia. South Asian J Cancer 2014; 3 (01) 87-91
• 4 Hughes TP, Hochhaus A, Branford S. et al IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS. Blood 2010; 116 (19) 3758-3765
• 5 Hanfstein B, Müller MC, Hehlmann R. et al SAKK; German CML Study Group. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML. Leukemia 2012; 26 (09) 2096-2102
• 6 Saglio G, Kim DW, Issaragrisil S. et al ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362 (24) 2251-2259
• 7 National Cancer Institute. Common Terminology Criteria for Adverse Events v 5.0. November 27, 2017
• 8 Jain P, Kantarjian H, Nazha A. et al Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013; 121 (24) 4867-4874
• 9 Hochhaus A, Rosti G, Cross NC. et al Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2016; 30 (01) 57-64
• 10 Branford S, Kim DW, Soverini S. et al Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 2012; 30 (35) 4323-4329
• 11 Hughes TP, Saglio G, Kantarjian HM. et al Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123 (09) 1353-1360
• 12 Lee S-E, Choi S-Y, Kim S-H. et al Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy. Leuk Lymphoma 2018; 59 (01) 105-113
• 13 Molica M, Canichella M, Alunni Fegatelli D. et al The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. Am J Hematol 2017; 92 (12) E661-E664
• 14 Yang X, Bai Y, Shi M. et al Validation of the EUTOS long-term survival score in Chinese chronic myeloid leukemia patients treated with imatinib: a multicenter real-world study. Cancer Manag Res 2020; 12: 1293-1301
• 15 Cortes JE, Jones D, O’Brien S. et al Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28 (03) 392-397
• 16 Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010; 3: 47
• 17 Zaidi U, Kaleem B, Borhany M. et al Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients. Cancer Manag Res 2019; 11: 1493-1502
• 18 Yu L, Qin YZ, Jiang Q. Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2017; 38 (09) 754-760